Canada markets open in 5 hours 51 minutes

Immuron Limited (ANW.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.0585-0.0005 (-0.85%)
As of 08:13AM CEST. Market open.
Full screen
Previous Close0.0590
Open0.0590
Bid0.0550 x 0
Ask0.0740 x 0
Day's Range0.0585 - 0.0585
52 Week Range0.0405 - 0.0991
Volume1,000
Avg. Volume0
Market Cap15.028M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.0130
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic

    MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical Research Center (NMRC) has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug (IND) application for a new oral therapeutic targeting Cam

  • GlobeNewswire

    Immuron North American Travelan® Sales up 494% and Global sales up 431%

    Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce the FY22 sales results o

  • GlobeNewswire

    Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

    MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has received notification of the Intent to Grant a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. Notification of the inte